Login to Your Account


Just six months after revealing a $10.3 million private placement to back development of a once-shelved therapy, Corbus Pharmaceuticals Holdings Inc. is preparing to submit an IND application to jump straight into a phase IIa trial of Resunab.

DUBLIN – Glionova AB, a Swedish start-up exploiting a novel mechanism of action in cancer, raised SEK42 million (US$5.7 million) in a series A round to take forward its lead drug, GLN-1001, which is in development for glioblastoma.
Triphase Accelerator Corp., a tiny drug developer with big backing from a Celgene Corp. deal, is pushing to bring economic rationality to the long haul between investigational new drug application filings and phase II proof of concept.
More NEWCO NEWS Headlines

Cast Your Vote

Has biotech’s bubble burst?: